Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

HCP

- PMLiVE

Biogen picks up another drug from wide-ranging Ionis alliance

Aims to follow success of Spinraza

- PMLiVE

Orphan drugs from Biogen and Amicus win UK Prix Galien

New medical technology category added for the first time

- PMLiVE

Spinraza lifts Biogen ahead of Alzheimer’s data

Continued strong growth for Biogen’s spinal muscular atrophy therapy Spinraza helped the company exceed revenue expectations in the third quarter, but pipeline disappointments kept its shares largely static.Spinraza (nusinersen) was...

Insights from the charity sector

Insights from the charity sector – from patient engagement to people-driven design

Marianne Guldbrandsen, Strategy Director at Cuttsy+Cuttsy and former Head of Innovation and Strategic Partnerships at Macmillan, discusses how people-driven research leads to truly patient-centred products and services, and what the...

Cuttsy + Cuttsy

- PMLiVE

Alnylam seeks fast-track filing with biomarker data

Early filing reflects FDA desire for faster approvals

Patient Engagement for the Life Sciences

Patient Engagement for the Life Sciences, written by Guy Yeoman and Mitchell Silva with editorial and design support from Cuttsy+Cuttsy, explains the ‘why’ and the ‘how’ of patient engagement. It...

Cuttsy + Cuttsy

Patient Engagement Book Image

Moving away from pharma’s paternalistic approach

New handbook makes the case for greater patient engagement in the development of new medicines

Cuttsy + Cuttsy

- PMLiVE

Genetic counsellors: the new healthcare influencers?

Blue Latitude Health explores the relationship between physicians and genetic counsellors, and the impact this has on turning precision medicine into a reality for oncology patients.

Blue Latitude Health

Rare diseases and orphan drugs: Our experience and expertise

We have designed a complimentary infographic outlining the market opportunity as well as our experience and expertise in the growing area of rare diseases and orphan drugs, which includes links to...

Research Partnership

- PMLiVE

Ionis and Roche gain PRIME status for Huntingdon’s disease candidate

More good news for Ionis after first drug approval

- PMLiVE

Spinraza keeps Biogen buoyant ahead of Alzheimer’s data

Biotech sees 9% growth ahead of potential landmark announcement

- PMLiVE

Sanofi’s rare blood disorder drug Cablivi set for European approval

Rare disease drug among notable CHMP recommendations

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links